Drugs / GBS Trivalent Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02690181 | Mar → Nov 2016 | group B streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02046148 | Mar 2014 → Dec 2015 | group B streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GBS Trivalent Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02690181 ↗ |
| Known as | Group B Streptococcus (GBS) trivalent vaccine | “Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of...” NCT02046148 ↗ |
| Modality | Vaccine | “Liquid formulation of a vaccine” NCT02046148 ↗ |
| Route | Intramuscular | “injected intramuscularly” NCT02046148 ↗ |